Distinct subsets of anti-pulmonary autoantibodies correlate with disease severity and survival in severe COVID-19 patients.
Autoantibody
Clinical outcome
IgG
IgM
Lung
Mortality
Multi-producer
Post-COVID
SARS-CoV-2
Severe COVID-19
Journal
GeroScience
ISSN: 2509-2723
Titre abrégé: Geroscience
Pays: Switzerland
ID NLM: 101686284
Informations de publication
Date de publication:
01 Sep 2023
01 Sep 2023
Historique:
received:
25
04
2023
accepted:
24
07
2023
medline:
1
9
2023
pubmed:
1
9
2023
entrez:
1
9
2023
Statut:
aheadofprint
Résumé
Autoantibodies targeting the lung tissue were identified in severe COVID-19 patients in this retrospective study. Fifty-three percent of 104 patients developed anti-pulmonary antibodies, the majority of which were IgM class, suggesting that they developed upon infection with SARS-CoV-2. Anti-pulmonary antibodies correlated with worse pulmonary function and a higher risk of multiorgan failure that was further aggravated if 3 or more autoantibody clones were simultaneously present (multi-producers). Multi-producer patients were older than the patients with less or no autoantibodies. One of the identified autoantibodies (targeting a pulmonary protein of ~ 50 kDa) associated with worse clinical outcomes, including mortality. In summary, severe COVID-19 is associated with the development of lung-specific autoantibodies, which may worsen the clinical outcome. Tissue proteome-wide tests, such as the ones applied here, can be used to detect autoimmunity in the post-COVID state to identify the cause of symptoms and to reveal a new target for treatment.
Identifiants
pubmed: 37656328
doi: 10.1007/s11357-023-00887-2
pii: 10.1007/s11357-023-00887-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Hungarian Academy of Sciences
ID : POST-COVID2021-16
Organisme : Hungarian Academy of Sciences
ID : POST-COVID2021-33
Organisme : Magyar Tudományos Akadémia
ID : NKM2022-30
Organisme : Hungarian Scientific Research Fund
ID : FK135327
Organisme : Hungarian Scientific Research Fund
ID : K142141
Organisme : Hungarian Scientific Research Fund
ID : K132623
Organisme : National Research, Development and Innovation Office
ID : TKP2021-EGA-19
Organisme : National Research, Development and Innovation Office
ID : TKP2021-EGA-20
Organisme : National Research, Development and Innovation Office
ID : TKP2020-NKA-04
Organisme : NKFIH
ID : K147243
Informations de copyright
© 2023. The Author(s).
Références
Raveendran AV, Jayadevan R, Sashidharan S. Long COVID: an overview. Diabetes Metab Syndr. 2021;15(3):869–75. https://doi.org/10.1016/j.dsx.2021.04.007 .
doi: 10.1016/j.dsx.2021.04.007
pubmed: 33892403
pmcid: 8056514
Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol. 2020;16(8):413–4. https://doi.org/10.1038/s41584-020-0448-7 .
doi: 10.1038/s41584-020-0448-7
pubmed: 32499548
pmcid: 7271827
Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021;33(2):155–62. https://doi.org/10.1097/bor.0000000000000776 .
doi: 10.1097/bor.0000000000000776
pubmed: 33332890
Fonseca DLM, Filgueiras IS, Marques AHC, Vojdani E, Halpert G, Ostrinski Y, et al. SARS-CoV-2 infection induces the production of autoantibodies in severe COVID-19 patients in an age-dependent manner. medRxiv. 2022. https://doi.org/10.1101/2022.12.04.22282902 .
Woodruff MC, Ramonell RP, Saini AS, Haddad NS, Anam FA, Rudolph ME, et al. Relaxed peripheral tolerance drives broad de novo autoreactivity in severe COVID-19. medRxiv. 2021. https://doi.org/10.1101/2020.10.21.20216192 .
Zuo Y, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med. 2020;12(570). https://doi.org/10.1126/scitranslmed.abd3876 .
Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595(7866):283–8. https://doi.org/10.1038/s41586-021-03631-y .
doi: 10.1038/s41586-021-03631-y
pubmed: 34010947
Son K, Jamil R, Chowdhury A, Mukherjee M, Venegas C, Miyasaki K, et al. Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms. Eur Respir J. 2022:2200970. https://doi.org/10.1183/13993003.00970-2022 .
Damoiseaux J, Dotan A, Fritzler MJ, Bogdanos DP, Meroni PL, Roggenbuck D, et al. Autoantibodies and SARS-CoV2 infection: the spectrum from association to clinical implication: Report of the 15th Dresden Symposium on Autoantibodies. Autoimmun Rev. 2022;21(3):103012. https://doi.org/10.1016/j.autrev.2021.103012 .
doi: 10.1016/j.autrev.2021.103012
pubmed: 34896650
Vlachoyiannopoulos PG, Magira E, Alexopoulos H, Jahaj E, Theophilopoulou K, Kotanidou A, et al. Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann Rheum Dis. 2020;79(12):1661–3. https://doi.org/10.1136/annrheumdis-2020-218009 .
doi: 10.1136/annrheumdis-2020-218009
pubmed: 32581086
Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann H-H, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585. https://doi.org/10.1126/science.abd4585 .
doi: 10.1126/science.abd4585
pubmed: 32972996
pmcid: 7857397
Combes AJ, Courau T, Kuhn NF, Hu KH, Ray A, Chen WS, et al. Global absence and targeting of protective immune states in severe COVID-19. Nature. 2021;591(7848):124–30. https://doi.org/10.1038/s41586-021-03234-7 .
doi: 10.1038/s41586-021-03234-7
pubmed: 33494096
pmcid: 8567458
Woodruff MC, Ramonell RP, Nguyen DC, Cashman KS, Saini AS, Haddad NS, et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat Immunol. 2020;21(12):1506–16. https://doi.org/10.1038/s41590-020-00814-z .
doi: 10.1038/s41590-020-00814-z
pubmed: 33028979
pmcid: 7739702
Fagyas M, Nagy B, Ráduly AP, Mányiné IS, Mártha L, Erdősi G, et al. The majority of severe COVID-19 patients develop anti-cardiac autoantibodies. GeroScience. 2022;44(5):2347–60. https://doi.org/10.1007/s11357-022-00649-6 .
doi: 10.1007/s11357-022-00649-6
pubmed: 36112333
pmcid: 9483490
Fagyas M, Bánhegyi V, Úri K, Enyedi A, Lizanecz E, Mányiné IS, et al. Changes in the SARS-CoV-2 cellular receptor ACE2 levels in cardiovascular patients: a potential biomarker for the stratification of COVID-19 patients. Geroscience. 2021;43(5):2289–304. https://doi.org/10.1007/s11357-021-00467-2 .
doi: 10.1007/s11357-021-00467-2
pubmed: 34674152
pmcid: 8529378
Fukushima K, Tsujino K, Futami S, Kida H. Natural autoantibodies in chronic pulmonary diseases. Int J Mol Sci. 2020;21(3). https://doi.org/10.3390/ijms21031138 .
Schattner A, Rager-Zisman B. Virus-induced autoimmunity. Rev Infect Dis. 1990;12(2):204–22. https://doi.org/10.1093/clinids/12.2.204 .
doi: 10.1093/clinids/12.2.204
pubmed: 2091619
Hansen KE, Arnason J, Bridges AJ. Autoantibodies and common viral illnesses. Semin Arthritis Rheum. 1998;27(5):263–71. https://doi.org/10.1016/S0049-0172(98)80047-4 .
doi: 10.1016/S0049-0172(98)80047-4
pubmed: 9572708
Yamamoto K. Possible mechanisms of autoantibody production and the connection of viral infections in human autoimmune diseases. Tohoku J Exp Med. 1994;173(1):75–82. https://doi.org/10.1620/tjem.173.75 .
doi: 10.1620/tjem.173.75
pubmed: 7528946
Barzilai O, Ram M, Shoenfeld Y. Viral infection can induce the production of autoantibodies. Curr Opin Rheumatol. 2007;19(6):636–43. https://doi.org/10.1097/BOR.0b013e3282f0ad25 .
doi: 10.1097/BOR.0b013e3282f0ad25
pubmed: 17917546
Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D. Autoimmune hepatitis: serum autoantibodies in clinical practice. Clin Rev Allergy Immunol. 2022;63(2):124–37. https://doi.org/10.1007/s12016-021-08888-9 .
doi: 10.1007/s12016-021-08888-9
pubmed: 34491531
Massabki PS, Accetturi C, Nishie IA, da Silva NP, Sato EI, Andrade LE. Clinical implications of autoantibodies in HIV infection. AIDS (London, England). 1997;11(15):1845–50. https://doi.org/10.1097/00002030-199715000-00009 .
doi: 10.1097/00002030-199715000-00009
pubmed: 9412703
Bolouri H, Speake C, Skibinski D, Long SA, Hocking AM, Campbell DJ, et al. The COVID-19 immune landscape is dynamically and reversibly correlated with disease severity. J Clin Invest. 2021;131(3). https://doi.org/10.1172/jci143648 .
Goronzy JJ, Weyand CM. Immune aging and autoimmunity. Cell Mol Life Sci. 2012;69(10):1615–23. https://doi.org/10.1007/s00018-012-0970-0 .
doi: 10.1007/s00018-012-0970-0
pubmed: 22466672
pmcid: 4277694
Carfì A, Bernabei R, Landi F, Group ftGAC-P-ACS. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603–5. https://doi.org/10.1001/jama.2020.12603 .
doi: 10.1001/jama.2020.12603
pubmed: 32644129
pmcid: 7349096
Tenforde MW, Kim SS, Lindsell CJ, Rose EB, Shapiro NI, Files DC, Gibbs KW, Erickson HL, Steingrub JS, Smithline HA, Gong MN, Aboodi MS, Exline MC, Henning DJ, Wilson JG, Khan A, Qadir N, Brown SM, Peltan ID, Rice TW, Hager DN, Ginde AA, Stubblefield WB, Patel MM, Self WH, Feldstein LR, IVY Network Investigators; CDC COVID-19 response team symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network — United States, March–June 2020. MMWR Morb Mortal Wkly Rep. 2020;69:993–8. https://doi.org/10.15585/mmwr.mm6930e1 .